2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 70

Data from Brazilian Fibromyalgia Patients Registry (EPIFIBRO) in 2014
Abstract Number: 2085

DC-STAMP Regulates Osteoclastogenesis through the Ca2+ /NFATc1 Axis
Abstract Number: 2067

De-Convolution of Whole Blood Transcriptomic Data from a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept in Systemic Lupus Erythematosus
Abstract Number: 1404

Death and Infection Rates Appear Reduced in a Modern Cohort of ICU Patients with Rheumatic Disease
Abstract Number: 1254

Deciphering the Immunome of Clinically Effective Immune Tolerization in Rheumatoid Arthritis
Abstract Number: 2257

Decline of Lung Function Is Associated with the Presence of Rheumatoid Factor in Korean Health Screening Subjects without Clinically Apparent Lung Diseases
Abstract Number: 2252

Declining Post-Arthroplasty Mortality after Total Knee Arthroplasty in the U.S.: A Time-Trends Study
Abstract Number: 3237

Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?
Abstract Number: 732

Decreased Disease Activity and Corticosteroid Usage and Improved Quality of Life during Belimumab Treatment in Patients with Systemic Lupus Erythematosus – a Prospective Real-Life Observational Study
Abstract Number: 1116

Decreased Expression of Negative Regulators of Toll-like Receptor Signaling and Increased TLR7 Responsiveness in Expanded IgD- CD27- B Cells from Systemic Lupus Erythematosus Patients
Abstract Number: 3023

Decreased Intracellular Calcium Flux in Follicular Helper T Cells after T Cell Receptor Stimulation
Abstract Number: 2643

Decreased Pain Level with Aging Leads to Underestimation of Disease Activity in Rheumatoid Arthritis
Abstract Number: 2529

Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Abstract Number: 502

Decreased Vaccine Responses in Rheumatoid Arthritis Patients Receiving Anti-TNF Treatment and Relationship to B Cell Subsets
Abstract Number: 1875

Deep Vein Thrombosis and Pulmonary Embolism in Systemic Sclerois

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].